Shots:
- The P-III BE SURE study involves assessing bimekizumab vs Humira (adalimumab) for 24wks. is followed until 56wks. in 478 adult patients with chronic PsO for at least 6 mos. before screening & with an affected body surface area of at least 10%, PASI of at least 12 & IGA score equal to or > 3 on a 5point scale
- Results: The study met its 1EPs & 2EPs, @16wks. PASI 90 (86.2% vs 47.2%); IGA 0/1 (85.3 % vs 57.2%); PASI 100 (60.8% vs 23.9%); PASI 100 @24wks. (66.8% vs 29.6%); PASI 90, PASI 100 and IGA 0/1 response rates were maintained through 1year with both q4w & q8w; skin clearance rates increased in patients who switched from adalimumab to bimekizumab @24wks., with response rates @56wks. comparable to patients treated with bimekizumab throughout the study
- Bimekizumab is an investigational humanized IgG1 mAb that selectively inhibits both IL-17A & IL-17F
Click here to read the full press release/ article | Ref: PRNewswire | Image: Pharma Journalist
The post UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-to-Severe Psoriasis first appeared on PharmaShots.